Impact of Aromatase Inhibitors on Bone Loss in Breast Cancer Patients
In a study conducted with Novartis Pharmaceuticals and the Mayo Clinic, Analysis Group Managing Principal Mei Sheng Duh, along with Dr. Edith Perez, a nationally known breast cancer authority, analyzed the impact of aromatase inhibitors (AIs) on bone loss in breast cancer patients. A novel hormonal therapy for treating breast cancer, AIs have been found to block estrogen production, resulting in bone loss. The study, published in the journal Clinical Breast Cancer, focuses on more than 12,000 patients and corroborates previous findings that AI therapies do carry an increased risk of bone loss. These findings are likely to have a significant impact on breast cancer treatment strategy, especially on monitoring and treatment to reduce bone loss.